摘要
目的 探讨二甲双胍治疗2型糖尿病合并动脉粥样硬化患者临床效果.方法 将84例2型糖尿病合并动脉粥样硬化患者按照随机数字表法分组为对照组与治疗组,每组42例.均加强饮食控制及健康教育、运动锻炼等.对照组采用格列齐特缓释片治疗;治疗组采用二甲双胍片治疗,均治疗6个月.分别于治疗前、治疗6个月后检测两组患者空腹血糖水平、餐后2h血糖水平,并检测两组患者经动脉内膜中层厚度（cIMT）、瘦素（LP）、脂联素（ADP）、超敏C反应蛋白（hs-CRP）、总胆固醇（TC）、几丁质酶-3样蛋白-1（YKL-40）、甘油三脂（TG）、低密度脂蛋白胆固醇（HDL-C）及高密度脂蛋白胆固醇（HDL-C）水平;记录两组治疗期间不良反应情况.结果 治疗组治疗6个月后空腹血糖水平、餐后2h血糖水平分别为（6.71±0.41） mmol/L、（8.82±0.61） mmol/L,明显低于对照组的（6.96±0.48） mmol/L、（9.58±0.57） mmol/L（t=2.56、5.89,P=0.01、0.00）;治疗组治疗6个月后cIMT、TC、TG、LDL-C明显低于对照组（t=5.36、6.46、9.10、2.31,P=0.00、0.00、0.00、0.02）,而HDL-C水平明显高于对照组（t=2.84,P=0.00）,两组患者治疗6个月后,除HDL-C较治疗前升高外,其余各项指标均明显低于治疗前（均P＜0.05）.治疗期间两组均未见不良反应.结论 2型糖尿病合并动脉粥样硬化患者采用二甲双胍片治疗效果显著,可有助于患者血糖水平及各项临床生化指标改善,并具有一定安全性.
Objective To investigate the clinical effect of mefformin tablets in the treatment of type 2 diabetes mellitus（T2DM） with atherosclerosis.Methods A total of 84 T2DM patients with atherosclerosis were divided into control group and treatment group according to the random number table method,42 cases in each group.All patients were given diet control,health education and exercise,etc..The control group was treated with gliclazide sustained-release tablets.The treatment group was treated with mefformin and treated for 6 months.The levels of fasting blood glucose（FBG） and 2 h postprandial blood glucose（2hPBG） were measured before and 6 months after treatment.The levels of intima-media thickness （cIMT）,leptin （LP）,adiponectin （TC）,chitinase-3-like protein-1 （YKL-40）,triglyceride （TG）,low density lipoprotein cholesterol （HDL-C） and high-density lipoprotein cholesterol （HDL-C） were measured.The adverse reactions were observed in the two groups.Results After treatment for 6 months,the levels of FBG and 2hPBG in the treatment group were （6.71 ±0.41） mmol/L and （8.82 ±0.61） mmol/L,respectively,which were significantly lower than those in the control group [（6.96 ± 0.48） mmol/L,（9.58 ± 0.57） mmol/L,t =2.56,5.89,P =0.01,0.00].The levels of cIMT,TC,TG and LDL-C in the treatment group were significantly lower than those in the control group at 6 months after treatment （t =5.36,6.46,9.10,2.31,P =0.00,0.00,0.00,0.02）.After 6 months of treatment,the HDL-C level of the treatment group was significantly higher than that of the control group （t =2.84,P =0.00）.After treatment for 6 months,HDL-C level in the two groups was significantly higher than before treatment,the other indicators in the two groups were significantly lower than before treatment （all P 〈 0.05）.There were no adverse reactions in the two groups during treatment.Conclusion Metformin in the treatment of T2DM patients with atherosclerosis has significant effect,it can improve blood glucose levels
出处
《中国基层医药》
CAS
2017年第23期3647-3651,共5页
Chinese Journal of Primary Medicine and Pharmacy
关键词
糖尿病
2型
动脉粥样硬化
二甲双胍
格列齐特
Diabetes mellitus, Type 2
Atherosclerosis
Metformin
Gliclazide sustained-release tablets
Blood sugar
